Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fortress Biotech, Inc.FBIO · Entity 6822 | Chief Financial Officer | September 21, 2021 | April 29, 2022 |
| TENAX THERAPEUTICS, INC.TENX · Entity 979 | Director | January 09, 2026 | January 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fortress Biotech, Inc.
Report date September 21, 2021 · Filed April 29, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001SEC Table I · non-derivative | Direct | 163,877 |
Reported balance
After 2021-09-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-09-21 · Sale · Disposed 28,292 · Balance 163,877 F1: In connection with the vesting of 62,500 shares on September 20, 2021, a total of 28,292 of such shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies. F2: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on September 21, 2021, was $3.11 to $3.14. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares sold at each separate price. F3: Of the 163,877 shares, 34,208 shares are restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the vesting of 62,500 shares on September 20, 2021, a total of 28,292 of such shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies.
F2: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on September 21, 2021, was $3.11 to $3.14. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares sold at each separate price.
F3: Of the 163,877 shares, 34,208 shares are restricted stock units.
TENAX THERAPEUTICS, INC.
Report date January 09, 2026 · Filed January 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2036-01-09 | Direct | 30,000 |
Reported balance
After 2026-01-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 30,000 · Balance 30,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $992.00 · Expires 2032-06-09 | Direct | 4 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 4 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.94 · Expires 2034-12-10 | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 100,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.75 · Expires 2035-07-01 | Direct | 80,000 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 80,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2026 Filed Jan 14, 2026 00:53 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $13.30 | $0.00 |
DisclosureSEC source: 0001713932-26-000001 · primary_doc.xml · derivative · entry 1 Hunter Robyn · CIK 0001713932 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-01-09 Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 12:08 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0001654954-25-007734 · section16.xml · derivative · entry 1 Hunter Robyn · CIK 0001713932 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-07-01 Read SEC document |
| December 10, 2024 Filed Dec 13, 2024 01:04 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0001654954-24-015475 · section16.xml · derivative · entry 1 Hunter Robyn · CIK 0001713932 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-12-10 Read SEC document |
| June 09, 2022 Filed Jun 11, 2022 01:19 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 6,250 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001654954-22-008237 · section16.xml · derivative · entry 1 Hunter Robyn · CIK 0001713932 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2032-06-09 Read SEC document |
| September 21, 2021 Filed Apr 29, 2022 20:25 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | SaleCommon Stock, par value $0.001 | 28,292 | $3.13 | $88,553.96 |
DisclosureSEC source: 0001104659-22-053623 · tm2213913-9_4seq1.xml · nonDerivative · entry 1 Hunter Robyn · CIK 0001713932 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,877 F1 · shares: In connection with the vesting of 62,500 shares on September 20, 2021, a total of 28,292 of such shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies. F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on September 21, 2021, was $3.11 to $3.14. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the 163,877 shares, 34,208 shares are restricted stock units. Read SEC document |
| September 22, 2020 Filed Sep 25, 2020 22:37 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | SaleCommon Stock, par value $0.001 | 28,450 | $4.38 | $124,611.00 |
DisclosureSEC source: 0001104659-20-109014 · tm2031853-1_4.xml · nonDerivative · entry 1 Hunter Robyn · CIK 0001713932 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,169 F1 · shares: In connection with the vesting of 62,500 shares on September 18, 2020, a total of 28,450 of such shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies. F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on September 22, 2020, was $4.36 to $4.41. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares sold at each separate price F3 · balance_after: Of the 192,169 shares, 62,500 shares are restricted stock units. Read SEC document |
| June 03, 2019 Filed Dec 31, 2019 21:02 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseCommon Stock, par value $0.001 | 2,297 | $1.10 | $2,526.70 |
DisclosureSEC source: 0001104659-19-077302 · tv530055_form4.xml · nonDerivative · entry 1 Hunter Robyn · CIK 0001713932 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,619 F1 · shares: Shares acquired as purchases made under the Company's Employee Stock Purchase Plan ("ESPP") during the ESPP offering period. F2 · balance_after: Does not include 21,437 shares automatically sold by the Company's plan administrator to cover taxes due upon vesting of certain shares. F3 · balance_after: Of the 220,619 shares, 125,000 shares are restricted stock units. Read SEC document |
| November 23, 2018 Filed Nov 30, 2018 22:26 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | SaleCommon Stock | 20,370 | $1.29 | $26,277.30 |
DisclosureSEC source: 0001144204-18-062675 · tv507899_4.xml · nonDerivative · entry 1 Hunter Robyn · CIK 0001713932 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,759 F1 · shares: In connection with the vesting of 62,500 shares on November 20, 2018, a total of 20,370 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the sale transactions on November 23, 2018, was $1.28 to $1.34. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the 239,759 shares, 187,500 shares are restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.